Last $17.90 USD
Change Today +0.15 / 0.85%
Volume 429.7K
LMNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Open
$17.74
Previous Close
$17.75
Day High
$18.03
Day Low
$17.72
52 Week High
10/10/14 - $21.69
52 Week Low
04/28/14 - $15.74
Market Cap
766.7M
Average Volume 10 Days
293.8K
EPS TTM
$0.63
Shares Outstanding
42.8M
EX-Date
--
P/E TM
28.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The company operates in two segments: Technology and Strategic Partnerships (TSP); and Assays and Related Products (ARP). The TSP segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a versatile multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The ARP segment develops and sells assays on xMAP, xTAG, and MultiCode technology for use on its installed base of systems. It provides various assay products that consist of a combination of chemical and biological reagents; and company’s proprietary bead technology used to perform diagnostic and research assays on samples. This segment’s products are focused on the human genetics, personalized medicine, and infectious disease segments of the molecular diagnostic testing market. Luminex Corporation serves pharmaceutical companies, clinical laboratories, and research and medical institutions in the United States, Europe, Asia, Canada, Australia, and internationally. The company has collaboration with Merck & Co. Inc. to develop a companion diagnostic device. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

731 Employees
Last Reported Date: 02/26/14
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $320.9K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $319.2K
Consultant
Total Annual Compensation: $700.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $345.6K
Compensation as of Fiscal Year 2013.

luminex corp (LMNX) Key Developments

Luminex Corporation Receives Health Canada Approval for its Comprehensive Genotyping Assay, xTAG® CYP2D6 Kit v3

Luminex Corporation announced it has received a Health Canada Class 3 Device License approval for its comprehensive genotyping assay, xTAG® CYP2D6 Kit v3. Identification of patient CYP2D6 genotypes can help clinicians individualize drug treatment by selecting appropriate therapies. Cytochrome P450 2D6 (CYP2D6) is a clinically important gene that encodes a drug-metabolizing enzyme. CYP2D6 metabolizes greater than 25% of the drugs in use present including some cardiovascular and anti-cancer drugs, anti-psychotics, anti-depressants, pain-medications, beta blockers, and antiarrhythmics. Variations in the CYP2D6 gene can result in distinct drug metabolizing profiles leading to potentially sub-optimal drug responses, such as drug toxicity, adverse drug reactions (ADRs), or inadequate therapeutic effect. Approximately 1.6% of patients admitted to acute care hospitals in Canada experience a serious adverse drug reaction. With almost 2.5 million annual hospital admissions in Canada of the type studied, statistics suggest that an estimated 40,000 serious adverse drug reactions occur annually in Canadian acute care hospitals. xTAG CYP2D6 Kit v3 is an in vitro diagnostic assay that analyzes a patient's CYP2D6 genotype from DNA extracted from a blood sample and is used to aid physicians in determining therapeutic strategy for drugs metabolized by the cytochrome P450 2D6 gene product. The assay is run on the flexible Luminex® 100/200 instrument. This new version of the kit optimizes performance on the 17 allele and features an updated software algorithm that detects all 17 genotypes that the assay is cleared for, including deletion and duplication genotypes. Additionally, another pharmacogenetic assay by Luminex, xTAG CYP2C19 Kit v3, received Health Canada approval in 2014. The CYP2C19 enzyme is responsible for metabolizing a variety of drugs used to treat ulcers, seizures, malaria, anxiety, and some antidepressants.

Luminex Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 08:30 AM

Luminex Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Nachum Shamir, Chief Executive Officer and President.

David S. Reiter Intends to Resign as Senior Vice President, General Counsel and Corporate Secretary from Luminex Corporation

On December 19, 2014, David S. Reiter announced Luminex Corporation of his intention to resign as the company's Senior Vice President, General Counsel and Corporate Secretary to pursue other interests. The company anticipates Mr. Reiter's resignation will be effective on or about April 1, 2015. Mr. Reiter's departure is amicable and is not due to any disagreement with the company, the company's new President and Chief Executive Officer or any matters relating to the company's operations, policies or practices. Mr. Reiter will be rejoining his independent legal practice. The company and Mr. Reiter have entered into a consulting agreement to be effective upon his resignation date pursuant to which Mr. Reiter will advise the company's Chief Executive Officer and General Counsel on legal matters and other transitional and consulting services to be reasonably requested and authorized by the company's Chief Executive Officer or General Counsel from time to time. The term of the consulting agreement will be until the end of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $17.90 USD +0.15

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $11.26 USD +0.34
Computer Programs & Systems Inc $58.94 USD +0.66
HealthStream Inc $28.85 USD +0.70
Meridian Bioscience Inc $17.78 USD +0.03
Quidel Corp $24.47 USD +0.11
View Industry Companies
 

Industry Analysis

LMNX

Industry Average

Valuation LMNX Industry Range
Price/Earnings 35.1x
Price/Sales 3.3x
Price/Book 2.5x
Price/Cash Flow 30.0x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.